Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 12/20 | 0.58 |
| ▸ | AXL | P30530 | 2/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.50 |
| ▸ | ITK | Q08881 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1663211 | 0.85 | AXL (0.60) | AXLHTR2AHTR2CHTR2BFGFR1 | |
| SCHEMBL17801064 | 0.82 | DCLK1 (0.65) | LRRK2AXLHTR2AHTR2CHTR2B | |
| SCHEMBL4006856 | 0.80 | AXL (0.55) | AXLHTR2AHTR2CHTR2BFGFR1 | |
| SCHEMBL2469031 | 0.80 | AXL (0.55) | AXLHTR2AHTR2CHTR2BFGFR1 | |
| SCHEMBL12193658 | 0.79 | MKNK1 (0.61) | LRRK2AXLHTR2AHTR2CHTR2B | |
| SCHEMBL31423230 | 0.79 | DCLK1 (0.65) | LRRK2AXLHTR2AHTR2CHTR2B | |
| SCHEMBL4008208 | 0.79 | DCLK1 (0.65) | LRRK2AXLHTR2AHTR2CHTR2B | |
| SCHEMBL2857828 | 0.79 | LRRK2 (0.54) | LRRK2TRPA1SCN5ASCN9AITK | |
| SCHEMBL5379650 | 0.79 | MAPK1 (0.61) | LRRK2TRPA1SCN5ASCN9AITK | |
| SCHEMBL2859279 | 0.78 | ITK (0.64) | LRRK2ITKMKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016089977-A1 | SUBSTITUTED INDAZOLE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORPORATION (US) | 2016-06-09 | — | — | WO | disclosed |
| EP-2642994-A2 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | Ligand Pharmaceuticals Incorporated (US) | 2013-10-02 | — | — | EP | disclosed |
| EP-2488486-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | Ligand Pharmaceuticals Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| WO-2012068406-A2 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2011046954-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARMACEUTICALS INC. (US) | 2011-04-21 | — | — | WO | disclosed |